600513 联环药业
已收盘 10-12 15:00:00
资讯
新帖
简况
联环药业（600513）10月8日主力资金净买入1.78亿元
证券之星 · 10-08
联环药业（600513）10月8日主力资金净买入1.78亿元
异动快报：联环药业（600513）10月8日9点30分触及涨停板
证券之星 · 10-08
异动快报：联环药业（600513）10月8日9点30分触及涨停板
股市必读：联环药业新发布《联环药业关于2026年半年度业绩说明会召开情况的公告》
证券之星 · 09-30
股市必读：联环药业新发布《联环药业关于2026年半年度业绩说明会召开情况的公告》
联环药业（600513）披露2026年半年度业绩说明会召开情况，9月28日股价上涨0.54%
证券之星 · 09-28
联环药业（600513）披露2026年半年度业绩说明会召开情况，9月28日股价上涨0.54%
股市必读：联环药业新发布《联环药业2026年第二次临时股东会决议公告》
证券之星 · 09-23
股市必读：联环药业新发布《联环药业2026年第二次临时股东会决议公告》
联环药业（600513）披露未来三年股东分红回报规划议案，9月22日股价上涨0.06%
证券之星 · 09-22
联环药业（600513）披露未来三年股东分红回报规划议案，9月22日股价上涨0.06%
联环药业上半年扭亏为盈 集采续采与创新药研发协同推进
证券日报 · 08-30
联环药业上半年扭亏为盈 集采续采与创新药研发协同推进
联环药业（600513）2026年中报简析：营收净利润同比双双增长，短期债务压力上升
证券之星 · 08-30
联环药业（600513）2026年中报简析：营收净利润同比双双增长，短期债务压力上升
股市必读：联环药业新发布《联环药业关于新增非同一控制下关联方及增加2026年度日常关联交易预计额度的公告》
证券之星 · 08-26
股市必读：联环药业新发布《联环药业关于新增非同一控制下关联方及增加2026年度日常关联交易预计额度的公告》
每周股票复盘：联环药业（600513）控股子公司拟申请2.715亿元授信
证券之星 · 08-16
每周股票复盘：联环药业（600513）控股子公司拟申请2.715亿元授信
股市必读：联环药业新发布《联环药业第九届董事会第二十六次临时会议决议公告》
证券之星 · 08-12
股市必读：联环药业新发布《联环药业第九届董事会第二十六次临时会议决议公告》
联环药业（600513）披露控股子公司向关联方借款暨关联交易公告，8月11日股价下跌1.53%
证券之星 · 08-11
联环药业（600513）披露控股子公司向关联方借款暨关联交易公告，8月11日股价下跌1.53%
股市必读：联环药业新发布《联环药业关于公司获得《药品注册证书》的公告》
证券之星 · 08-10
股市必读：联环药业新发布《联环药业关于公司获得《药品注册证书》的公告》
每周股票复盘：联环药业（600513）两款产品拟中选集采
证券之星 · 08-09
每周股票复盘：联环药业（600513）两款产品拟中选集采
联环药业（600513）披露公司获得《药品注册证书》，8月7日股价上涨2.03%
证券之星 · 08-07
联环药业（600513）披露公司获得《药品注册证书》，8月7日股价上涨2.03%
联环药业最新公告：获得乳果糖口服溶液药品注册证书
证券之星 · 08-07
联环药业最新公告：获得乳果糖口服溶液药品注册证书
联环药业(600513.SH)：布美他尼注射剂等药品拟中选全国药品集中采购
智通财经 · 08-03
联环药业(600513.SH)：布美他尼注射剂等药品拟中选全国药品集中采购
每周股票复盘：联环药业（600513）创新药LH-1801提交Pre-NDA申请
证券之星 · 08-02
每周股票复盘：联环药业（600513）创新药LH-1801提交Pre-NDA申请
异动快报：联环药业（600513）7月30日10点2分触及涨停板
证券之星 · 07-30
异动快报：联环药业（600513）7月30日10点2分触及涨停板
联环药业（600513）披露投资者关系活动记录表，7月27日股价上涨3.37%
证券之星 · 07-27
联环药业（600513）披露投资者关系活动记录表，7月27日股价上涨3.37%
加载更多
公司概况
公司名称：
江苏联环药业股份有限公司
所属行业：
医药制造业
上市日期：
2003-03-19
主营业务：
江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。
发行价格：
7.88
{"stockData":{"symbol":"600513","market":"SH","secType":"STK","nameCN":"联环药业","latestPrice":15.62,"timestamp":1791788400000,"preClose":16.28,"halted":0,"volume":22687030,"delay":0,"changeRate":-0.0405,"floatShares":285000000,"shares":285000000,"eps":-0.1674,"marketStatus":"已收盘","change":-0.66,"latestTime":"10-12 15:00:00","open":16.33,"high":16.38,"low":15.43,"amount":358000000,"amplitude":0.0584,"askPrice":15.63,"askSize":35,"bidPrice":15.62,"bidSize":87,"shortable":0,"etf":0,"ttmEps":-0.1674,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":5,"adr":0,"adjPreClose":16.28,"symbolType":"stock","openAndCloseTimeList":[[1791768600000,1791775800000],[1791781200000,1791788400000]],"highLimit":17.91,"lowLimit":14.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":285456270,"isCdr":false,"pbRate":3.53,"roa":"--","roe":"0.82%","epsLYR":-0.34,"committee":0.731459,"marketValue":4459000000,"turnoverRate":0.0795,"status":1,"floatMarketCap":4459000000},"requestUrl":"/m/hq/s/600513","defaultTab":"news","newsList":[{"id":"2673502903","title":"联环药业（600513）10月8日主力资金净买入1.78亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673502903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673502903?lang=zh_cn&edition=full","pubTime":"2026-10-08 15:21","pubTimestamp":1791444082,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，联环药业报收于16.6元，上涨10.01%，换手率15.99%，成交量45.63万手，成交额7.46亿元。10月8日的资金流向数据方面，主力资金净流入1.78亿元，占总成交额23.91%，游资资金净流出5595.92万元，占总成交额7.5%，散户资金净流出1.22亿元，占总成交额16.41%。联环药业主营业务：化学药品的研发、生产及销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800013971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673414460","title":"异动快报：联环药业（600513）10月8日9点30分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2673414460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673414460?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:35","pubTimestamp":1791423331,"startTime":"0","endTime":"0","summary":"证券之星10月8日盘中消息，9点30分联环药业（600513）触及涨停板。其所属行业化学制药目前上涨。领涨股为键凯科技。该股为流感，新冠病毒防治，江苏国企改革概念热股，当日流感概念上涨1.28%，新冠病毒防治概念上涨0.83%，江苏国企改革概念上涨0.77%。9月30日的资金流向数据方面，主力资金净流入261.12万元，占总成交额1.74%，游资资金净流出748.69万元，占总成交额4.98%，散户资金净流入487.57万元，占总成交额3.24%。近5日资金流向一览见下表：联环药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800004248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671244924","title":"股市必读：联环药业新发布《联环药业关于2026年半年度业绩说明会召开情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671244924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671244924?lang=zh_cn&edition=full","pubTime":"2026-09-30 02:55","pubTimestamp":1790708110,"startTime":"0","endTime":"0","summary":"公司公告汇总：联环药业于9月28日召开2026年半年度业绩说明会，确认上半年实现扭亏为盈，业绩增量主要来自新获批品种放量及并购整合协同；LH-1801已提交材料待CDE受理。公司公告汇总联环药业关于2026年半年度业绩说明会召开情况的公告江苏联环药业股份有限公司于2026年9月28日召开2026年半年度业绩说明会，公司董事长、总经理、财务总监及董事会秘书出席，就公司发展规划、研发创新等与投资者进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670088253","title":"联环药业（600513）披露2026年半年度业绩说明会召开情况，9月28日股价上涨0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670088253","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670088253?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:23","pubTimestamp":1790605394,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，联环药业报收于14.85元，较前一交易日上涨0.54%，最新总市值为42.39亿元。该股当日开盘14.77元，最高15.1元，最低14.55元，成交额达1.01亿元，换手率为2.39%。近日，联环药业发布《关于2026年半年度业绩说明会召开情况的公告》。公告显示，江苏联环药业股份有限公司于2026年9月28日召开2026年半年度业绩说明会，公司董事长、总经理、财务总监及董事会秘书出席，就公司发展规划、研发创新等与投资者进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800035063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669121212","title":"股市必读：联环药业新发布《联环药业2026年第二次临时股东会决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669121212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669121212?lang=zh_cn&edition=full","pubTime":"2026-09-23 02:50","pubTimestamp":1790103020,"startTime":"0","endTime":"0","summary":"公司公告汇总：联环药业于2026年9月22日召开第二次临时股东会，审议通过《未来三年股东分红回报规划的议案》，同意票占比99.3988%。公司公告汇总联环药业2026年第二次临时股东会决议公告江苏联环药业股份有限公司于2026年9月22日召开2026年第二次临时股东会，会议由董事长钱振华主持，采用现场与网络投票结合方式召开，出席会议的股东及代理人共434人，代表有表决权股份119,844,089股，占公司总股本的41.9833%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669128542","title":"联环药业（600513）披露未来三年股东分红回报规划议案，9月22日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669128542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669128542?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:24","pubTimestamp":1790087058,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，联环药业报收于15.39元，较前一交易日上涨0.06%，最新总市值为43.93亿元。该股当日开盘15.36元，最高15.56元，最低15.15元，成交额达1.31亿元，换手率为3.0%。近日，联环药业发布《2026年第二次临时股东会决议公告》。公告显示，公司于2026年9月22日召开2026年第二次临时股东会，审议通过了《联环药业未来三年股东分红回报规划的议案》。出席会议的股东及代理人共434人，代表有表决权股份119,844,089股，占公司总股本的41.9833%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200041856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"联环药业上半年扭亏为盈 集采续采与创新药研发协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044177?lang=zh_cn&edition=full","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","APXH","LFSC","BK0239","WRND","BIOY","BK4585","GDOC","SBIO","XLVI","PBE","GSKH","IBB","BBP","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663984048","title":"联环药业（600513）2026年中报简析：营收净利润同比双双增长，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663984048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663984048?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:05","pubTimestamp":1788041153,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期联环药业发布2026年中报。截至本报告期末，公司营业总收入15.71亿元，同比上升22.21%，归母净利润1052.18万元，同比上升126.29%。按单季度数据看，第二季度营业总收入7.6亿元，同比上升15.59%，第二季度归母净利润409.71万元，同比上升106.49%。本报告期联环药业短期债务压力上升，流动比率达0.93。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766930","title":"股市必读：联环药业新发布《联环药业关于新增非同一控制下关联方及增加2026年度日常关联交易预计额度的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766930","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766930?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:25","pubTimestamp":1787707543,"startTime":"0","endTime":"0","summary":"公司公告汇总：联环药业新增国药控股扬州有限公司及其子公司为非同一控制下关联方，增加2026年度日常关联交易预计额度合计2045万元。公司公告汇总联环药业关于新增非同一控制下关联方及增加2026年度日常关联交易预计额度的公告江苏联环药业股份有限公司于2026年8月24日召开独立董事专门会议及第九届董事会第二十七次临时会议，审议通过《关于新增非同一控制下关联方及增加2026年度日常关联交易预计额度的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600016491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659759031","title":"每周股票复盘：联环药业（600513）控股子公司拟申请2.715亿元授信","url":"https://stock-news.laohu8.com/highlight/detail?id=2659759031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659759031?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:39","pubTimestamp":1786815548,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，联环药业报收于17.62元，较上周的18.07元下跌2.49%。本周，联环药业8月10日盘中最高价报18.78元。本周关注点公司公告汇总：全资子公司控股的四川龙一医药拟申请不超过2.715亿元综合授信。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658120779","title":"股市必读：联环药业新发布《联环药业第九届董事会第二十六次临时会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658120779","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658120779?lang=zh_cn&edition=full","pubTime":"2026-08-12 01:45","pubTimestamp":1786470315,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，联环药业报收于17.4元，下跌1.53%，换手率8.12%，成交量23.19万手，成交额4.09亿元。当日关注点交易信息汇总：8月11日主力资金净流出537.99万元，占总成交额1.31%。公司公告汇总：控股子公司拟向关联方借款1000万元，年利率2.5%（含税），期限不超过3个月，由自然人股东以股权按比例提供担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200001884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916245","title":"联环药业（600513）披露控股子公司向关联方借款暨关联交易公告，8月11日股价下跌1.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916245","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916245?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:16","pubTimestamp":1786457786,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，联环药业报收于17.4元，较前一交易日下跌1.53%，最新总市值为49.67亿元。近日，联环药业发布《关于控股子公司向关联方借款暨关联交易的公告》。公告显示，公司控股子公司联环（南京）医疗科技有限公司因日常经营周转需要，拟向关联方江苏联环健康产业管理发展有限公司借款人民币1,000万元，借款期限不超过3个月，年利率为2.5%（含税），到期一次性还本付息。本次交易构成关联交易，但不构成重大资产重组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670042","title":"股市必读：联环药业新发布《联环药业关于公司获得《药品注册证书》的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670042","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670042?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:00","pubTimestamp":1786298450,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，联环药业报收于18.07元，上涨2.03%，换手率11.76%，成交量33.57万手，成交额6.02亿元。当日关注点交易信息汇总：8月7日主力资金净流入517.74万元，占总成交额0.86%。公司公告汇总：联环药业获乳果糖口服溶液《药品注册证书》，按化学药品4类申报，视同通过仿制药一致性评价。该药品适用于慢性或习惯性便秘、肝性脑病的治疗和预防。2025年全国二级以上医院该药品销售额达5.63亿元。公司针对该药品的研发投入约529.70万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658967580","title":"每周股票复盘：联环药业（600513）两款产品拟中选集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2658967580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658967580?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:27","pubTimestamp":1786213630,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，联环药业报收于18.07元，较上周的17.32元上涨4.33%。本周，联环药业8月7日盘中最高价报18.3元。拟中选产品采购周期至2029年12月31日，具体采购协议签署方式由各省确定。联环药业近日取得国家药监局核准签发的乳果糖口服溶液《药品注册证书》，按化学药品4类申报，视同通过仿制药质量和疗效一致性评价。2025年全国二级以上医院该药品销售额达5.63亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657441686","title":"联环药业（600513）披露公司获得《药品注册证书》，8月7日股价上涨2.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657441686","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657441686?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:24","pubTimestamp":1786112684,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，联环药业报收于18.07元，较前一交易日上涨2.03%，最新总市值为51.58亿元。该股当日开盘17.4元，最高18.3元，最低17.3元，成交额达6.02亿元，换手率为11.76%。近日，江苏联环药业股份有限公司收到国家药品监督管理局核准签发的乳果糖口服溶液《药品注册证书》，该药品按化学药品4类申报，视同通过仿制药质量和疗效一致性评价。2025年全国二级以上医院该药品销售额达5.63亿元。公司针对该药品的研发投入约529.70万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657485616","title":"联环药业最新公告：获得乳果糖口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657485616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657485616?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:51","pubTimestamp":1786092683,"startTime":"0","endTime":"0","summary":"联环药业(600513.SH)公告称，公司近日收到国家药监局核准签发的乳果糖口服溶液(200ml:133.4g/15ml:10g)《药品注册证书》，该药品适用于慢性或习惯性便秘及肝性脑病。本次获批视同通过仿制药质量和疗效一致性评价，进一步丰富了公司产品线，但预计不会对近期经营业绩产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656321059","title":"联环药业(600513.SH)：布美他尼注射剂等药品拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656321059","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656321059?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:33","pubTimestamp":1785746004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联环药业(600513.SH)发布公告，公司及控股子公司新乡市常乐制药有限责任公司参加了由国家组织药品联合采购办公室组织开展的第十二批全国药品集中采购投标工作。根据联采办发布的《第12批国家组织药品集中带量采购拟中选结果公示》，公司及控股子公司常乐制药药品：美阿沙坦口服常释剂型、布美他尼注射剂、维生素B6注射剂中选本次集中采购。本次药品集中采购是联采办组织的第十二批国家药品集中采购，在执行上要求医疗机构优先使用集中采购中选品种，并确保完成约定采购量。公司及子公司后续签订采购合同并实施后，将有利于上述产品快速打开国内销售市场，提高市场占有率，提升公司的品牌影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656161723","title":"每周股票复盘：联环药业（600513）创新药LH-1801提交Pre-NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2656161723","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656161723?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:15","pubTimestamp":1785608113,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，联环药业报收于17.32元，较上周的15.42元上涨12.32%。本周，联环药业7月31日盘中最高价报17.55元。本周共计1次涨停收盘，无跌停收盘情况。本周关注点来自公司公告汇总：创新药LH-1801已完成与达格列净的头对头Ⅲ期临床试验，目前已提交Pre-NDA沟通交流申请。爱普列特原料库存管理稳定，产品上市二十余年持续增长，2025年销售额同比增长6.2%，已纳入多项诊疗指南。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1161","BK1574","BK0239","600513","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655551849","title":"异动快报：联环药业（600513）7月30日10点2分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2655551849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655551849?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:11","pubTimestamp":1785377461,"startTime":"0","endTime":"0","summary":"证券之星7月30日盘中消息，10点2分联环药业（600513）触及涨停板。其所属行业化学制药目前上涨。领涨股为海南海药。该股为化妆品，江苏国企改革，医药概念热股，当日化妆品概念上涨1.26%，江苏国企改革概念上涨0.89%，医药概念上涨0.84%。7月29日的资金流向数据方面，主力资金净流出1804.13万元，占总成交额5.37%，游资资金净流入782.53万元，占总成交额2.33%，散户资金净流入1021.6万元，占总成交额3.04%。近5日资金流向一览见下表：联环药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000009912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045732","title":"联环药业（600513）披露投资者关系活动记录表，7月27日股价上涨3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654045732?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:15","pubTimestamp":1785161759,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，联环药业报收于15.94元，较前一交易日上涨3.37%，最新总市值为45.5亿元。该股当日开盘15.0元，最高16.08元，最低15.0元，成交额达3.3亿元，换手率为7.36%。近日，联环药业发布投资者关系活动记录表。公告显示，公司于2026年7月24日举行投资者关系活动，就爱普列特原料库存管理、销售增长及市场前景作出说明，该产品上市二十余年持续增长，2025年销售额同比增长6.2%，已纳入多项诊疗指南。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791835986986,"stockEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0604},{"period":"3month","weight":-0.1235},{"period":"6month","weight":-0.3392},{"period":"1year","weight":-0.1675},{"period":"ytd","weight":-0.1429}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏联环药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38865人(较上一季度减少8.90%)","perCapita":"7344股","listingDate":"2003-03-19","address":"江苏省扬州市邗江区生物健康产业园健康一路9号","registeredCapital":"28545万元","survey":" 江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。","listedPrice":7.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联环药业,600513,联环药业股票,联环药业股票老虎,联环药业股票老虎国际,联环药业行情,联环药业股票行情,联环药业股价,联环药业股市,联环药业股票价格,联环药业股票交易,联环药业股票购买,联环药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}